TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Dinoprostone Administration Prior to an Intrauterine Device Insertion in Multiparous Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* multiparous women aged over 18 years of age requesting an IUD for contraception, had a negative pregnancy test.~Exclusion Criteria:~* currently pregnant or were pregnant within 6 weeks of study entry~* had a prior attempted or successful IUD insertion~* had a history of a cervical procedure such as cone biopsy, Loop electrosurgical excision procedure, or cryotherapy~* any World Health Organization Medical Eligibility Criteria category 3 or 4 precaution to an IUD~* active vaginitis or cervicitis~* undiagnosed abnormal uterine bleeding~* pelvic inﬂammatory disease within the last 3 months~* ﬁbroids or other uterine abnormalities distorting the uterine cavity~* contraindication or allergy to dinoprostone.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- dinoprostone (Type: EXPERIMENTAL): 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
- placebo (Type: PLACEBO_COMPARATOR): one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Estradiol Trial in Women With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patients of potential child-bearing age (Pre-menopausal and Post-menarche)~* Female patients who have a current diagnosis of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder (not in manic phase)~* Female patients who score more than or equal to 60 on PANSS rating scale~* Female patients who are able to give informed consent~Exclusion Criteria:~* Female patients who are pregnant or lactating.~* Female patients with known severe abnormalities in the hypothalamo-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, or other serious medical conditions which would contraindicate estrogen use.~* Female patients already taking estrogen preparations such as the oral contraceptive pill~* Post-menopausal or pre-menarche female patients.~* Female patients whose psychotic illness is due to illicit drugs or who have a history of consistent substance abuse or dependence during the last 6 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with chronic hepatitis B:~  * Serum hepatitis B surface antigen positive for at least 6 months~ * Serum hepatitis B e antigen positive~ * Serum negative for hepatitis B surface and e antibodies~ * Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000 IU/mL~ * Alanine aminotransferase (ALT) 2- to 10-times the upper limit of normal~* Compensated liver disease with certain minimum hematological and serum biochemical criteria~Exclusion Criteria:~* Significant hepatic disease from an etiology other than hepatitis B virus~* Antiviral treatment for hepatitis within previous 6 months~* History of severe psychiatric disease, especially depression~* Unstable or significant cardiovascular disease~* Prolonged exposure to known hepatotoxins such as alcohol or drugs~* Any condition that could interfere with the subject participating in and completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PEG 1.0 mcg/kg weekly (QW) * 24 weeks (Type: ACTIVE_COMPARATOR): PegIntron 1.0 mcg/kg weekly (QW) \* 24 weeks + 24 weeks follow-up
- PEG 1.5 mcg/kg QW * 24 wks (Type: EXPERIMENTAL): PegIntron 1.5 mcg/kg QW \* 24 wks + 24 wks follow-up
- PEG 1.5 mcg/kg QW * 48 wks (Type: EXPERIMENTAL): PegIntron 1.5 mcg/kg QW \* 48 wks + 24 wks follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women with metastatic (Stage IV) breast cancer, or with locally advanced breast cancer (Stages IIIA \> 10 cm, or Stages IIIB and IIIC) that did not respond to first-line anthracycline-based chemotherapy, for whom docetaxel is a recommended therapy~* Presence of measurable or evaluable disease~* Adequate organ function~* Ability to swallow intact study drug capsules~* Zubrod Performance Status of 0-1 with at least a 3 month life expectancy~* Appropriate time must have elapsed since prior anti-neoplastic therapy with resolution of acute toxicity~Exclusion Criteria:~* Concurrent treatment with hormonal therapy intended to treat cancer~* Radiotherapy within 7 days prior to first dose~* Symptomatic central nervous system, and/or epidural metastases or symptomatic carcinomatous meningitis or with radiation treatment completed within the past 8 weeks~* Serious comorbid illness which will limit the ability of the patient to safely receive anticancer treatment~* Patients who are pregnant or nursing~* Confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-0752, Docetaxel, Pegfilgrastim (Type: EXPERIMENTAL): MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 years (including boundary values);~2. Have behavioral ability, and voluntarily participate in this clinical study, and sign the informed consent form (ICF);~3. Performance status (ECOG) score 0-1 points (see Appendix 1 for details);~4. Basal heart rate 60-100 beats/min (including boundary values);~5. Blood pressure measurement \< hypertension grade 1 level (including a history of hypertension, systolic blood pressure \< 140 and diastolic blood pressure \< 90 mmHg by exercise or drug treatment);~6. Patients with confirmed solid tumors;~7. Patients who must have at least one image-measurable lesion according to the evaluation criteria for solid tumors (RECISTv1.1);~8. Imaging results show that at least one tumor lesion can be needle biopsy or surgical treatment to obtain specimens (enhanced CT, enhanced MRI or 18F-FDG PET/CT results are acceptable);~9. Patients with immunohistochemical CD8 results within the past month;~Exclusion Criteria:~1. Those who are unable to follow this clinical trial protocol well enough to make visits, or undergo relevant examinations, or treatment.~2. Those who have extremely poor nutritional status and cannot tolerate the trial~3. Those with comorbid major diseases or other malignancies (except those that have healed by one year or do not require additional treatment)~4. Those with known severe allergy to SNA006, similar drugs or excipients. Specialized conditions~5. Patients who have undergone previous splenectomy or splenic disease such as hypersplenism or splenomegaly~6. Patients with brain metastases.~7. Serum virology tests: positive results for any of hepatitis B virus surface antigen, hepatitis C virus antibodies, syphilis-specific antibodies or those who cannot be determined to be negative for human immunodeficiency virus antibodies~8. Patients who have not recovered from a serious infection~9. Patients with drug/alcohol abuse, severe mental disorders~10. Those with claustrophobia, emotional instability, acute persistent spasticity or inability to keep both arms up and lying flat for 15-30 minutes~11. Those who have participated in any other clinical trial within 3 months prior to screening~12. Women who are pregnant or breastfeeding.~13. Those who, in the opinion of the investigator, are not suitable to participate in this clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 68Ga-NODAGA-SNA006 (Type: EXPERIMENTAL): A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a clinical diagnosis of type 2 diabetes mellitus~* Has an HbA1c \>7.0% and ≤10.0%~* Has a BMI of ≥25 kg/m\^2 and ≤50 kg/m\^2~* Has been on a regimen of insulin for less than 6 months and is taking less than 50 U total of insulin per day, OR has not been on a pre existing insulin regimen and is a candidate for the initiation of basal insulin therapy~Exclusion Criteria:~* Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months~* Requires the use of drugs that stimulate gastrointestinal motility~* Has been previously treated with Symlin (or has participated in a Symlin clinical study)~* Is currently being treated with any of the following medications: \*Over-the-counter antiobesity agents (including, but not limited to, herbal supplements) or prescription antiobesity agents (including orlistat \[Xenical®\] and sibutramine \[Meridia®\]); \*Oral, intravenous, or intramuscular systemic steroids by oral or potent inhaled or intrapulmonary steroids that are known to have a high rate of systemic absorption; \*Drugs that directly affect gastrointestinal motility, including but not limited to: dopamine antagonists (e.g., metoclopramide \[Reglan®\]), opiates or anticholinergics; and chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives; \*Investigational medications~* Has a history or presence of any of the following: \*Eating disorders (including anorexia and/or bulimia); \*Bariatric surgery (gastric bypass, gastric banding, or gastroplasty)~* Is currently enrolled in a weight-loss program or plans to enroll in a weight-loss program before termination of the study~* Has donated blood within 30 days of study start or plans to donate blood during the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Calcium and Phytate on Zinc Absorption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Average weight for height~Exclusion Criteria:~* Medications other than birth control pills or hormone replacement therapy,~* Pregnancy within last 6 months

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Overall Study (Type: EXPERIMENTAL): Participants consumed 4 experimental diets for 4 weeks each in randomized order

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-55 age~* Diagnosis of RMS (McDonald criteria 2010)~* Active disease~* Expanded disability status scale (EDSS) 0-5.5 (inclusive) at screening~Exclusion Criteria:~* Treatment with prior Anti-cluster of differentiate 20 (CD20) or other B cell directed treatment~* Treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and stem cell transplantation~* Diagnosed with Primary Progressive MS (PPMS)~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ublituximab + Oral Placebo (Type: EXPERIMENTAL): Participants were administered ublituximab 150 milligrams (mg), intravenous (IV) infusion over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo once daily (QD) from Day 1 up to the last day of Week 95.
- Teriflunomide + IV Placebo (Type: ACTIVE_COMPARATOR): Participants were administered teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed leiomyosarcoma (LMS) or other soft tissue sarcoma~  * No gastrointestinal stromal tumors, chondrosarcoma, Kaposi's sarcoma, Ewing's sarcoma, osteosarcoma, or mesotheliomas~* Recurrent or progressive disease defined as an increase in the size of any existing tumor (or the development of new tumors) that is not amenable to definitive surgical therapy~* No prior chemotherapy OR~* Failed no more than 2 prior chemotherapy regimens for LMS of the uterus or other soft tissue sarcoma~* Bidimensionally measurable disease by physical examination or medical imaging techniques~  * Ascites and pleural effusions are not considered measurable disease~* No uncontrolled CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~Renal:~* Creatinine no greater than 2.0 mg/dL~Other:~* No active or uncontrolled infection~* No other prior malignancy except non-metastatic squamous cell or basal cell skin cancer or non-invasive carcinoma in situ of the cervix~* No history of grade 3 or 4 peripheral neuropathy~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy~* No prior gemcitabine or docetaxel~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 6 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented Clinical diagnosis of Erectile Dysfunction (ED) by International Index of Erectile Function (IIEF) Erectile Function (EF) Domain score less than or equal to 25.~* Subjects must be in a stable relationship~Exclusion Criteria:~* Subject with resting sitting hypotension (BP \<90/50 mmHg) or hypertension (BP\>170/110 mmHg) and orthostatic hypotension.~* Subjects receiving any PDE (Phosphodiesterase)-5 inhibitors within 4 weeks prior to the date of screening.~* Subjects with severe hepatic impairment, a known history of retinitis pigmentare.~* Subjects with significant cardiovascular disease in the last 3 months (per medical history.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label (Type: ACTIVE_COMPARATOR): Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chest radiograph or CT thorax (within 1 year of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease, in the opinion of the principal investigator or the subinvestigator~* Has chronic cough (defined as duration of \>8 weeks after onset of cough symptoms) for \<12 months prior to the screening visit (\<14 months after onset of cough symptoms)~* Has a diagnosis of refractory chronic cough or unexplained chronic cough~* Female participants are not pregnant, not breastfeeding, not of childbearing potential, or agree to follow contraceptive guidance~Exclusion Criteria:~* Is a current smoker~* Has given up smoking within 12 months of screening~* Is a former smoker with a smoking history greater than 20 pack-years (1 pack of 20 cigarettes per day for 20 years)~* Has a history of respiratory tract infection or recent change in pulmonary status within 4 weeks of screening~* Has a history of chronic bronchitis, defined as cough that produces \>1 tablespoon of phlegm, that occurs every day for at least 3 months in a row~* Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or cervical cancer~* Is a user of recreational or illicit drugs or a recent history (within the last year) of drug or alcohol abuse~* Has a history of anaphylaxis or cutaneous adverse drug reaction to sulfonamide-containing drugs~* Has a known allergy to gefapixant or its excipients~* Has donated or lost ≥1 unit (\~300 mL) of blood within 8 weeks prior to first dose of gefapixant~* Has previously received gefapixant~* Is currently participating or has participated in an interventional clinical study within 30 days of participating in this current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gefapixant (Type: EXPERIMENTAL): Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adults meeting DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria for Bipolar I Disorder (currently with manic or mixed symptoms)~Exclusion Criteria:~Ultra rapid cyclers and subjects with significant cardiovascular disease including history of QT prolongation and/or congenital long QT syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ziprasidone (Type: EXPERIMENTAL): Active treatment, double-blind, randomized arm
- Placebo (Type: PLACEBO_COMPARATOR): Placebo treatment, double-blind, randomized arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete